ArticleScientific reports2025
c-Myc-dependent LAMP3 regulates the proliferation, metastasis and metabolic reprogramming of tongue squamous cell carcinoma.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To delve into the role and molecular mechanism of lysosome-associated membrane protein 3 (LAMP3) in tongue squamous cell carcinoma (TSCC). Differential expression of LAMP3 in TSCC from GEO microarray was analyzed, and pathway enrichment analysis of LAMP3 was performed utilizing GSEA. LAMP3 expression was detected by western blot, immumohistochemical staining and qRT-PCR. LAMP3 knockdown plasmid was constructed for a variety of biological function assays to verify the involvement of LAMP3 in TSCC. The upstream transcription factors and binding sites of LAMP3 were bioinformatically predicted. Dual luciferase reporter gene assay was applied to check the presence of c-Myc binding to the promoter region of LAMP3 and the regulation of its transcription. Further, a xenograft tumor model was developed to corroborate the impact of LAMP3 on tumor growth in vivo. LAMP3 expression was enhanced in TSCC tissues and cells. LAMP3 knockdown attenuated TSCC cell proliferation, DNA replication and metastatic capacity while induced glucose metabolism reprogramming in vitro. Meanwhile, LAMP3 depletion contributed to the delay of tumor progression in vivo. c-Myc was found bind to the LAMP3 promoter region to positively modulate LAMP3 transcriptional expression. LAMP3 regulated by c-Myc enhanced TSCC cell proliferation, DNA replication capacity while induced glucose metabolism reprogramming, suggesting a potential target for clinical trials in TSCC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.